Akums Drugs and Pharmaceuticals Limited has released the Monitoring Agency report for the quarter ended March 31, 2026. The report confirms that the company maintains a stable financial position regarding its Initial Public Offer (IPO) proceeds. With Rs 6,421.80 million in revised net proceeds, the company has effectively reallocated certain funds to growth initiatives and general corporate purposes, while key debt repayment objectives were successfully met in previous quarters.
Report Overview
CRISIL Ratings Limited, serving as the Monitoring Agency, has filed its report regarding the utilization of proceeds from Akums Drugs and Pharmaceuticals Limited’s Initial Public Offer. The document confirms that there has been no deviation from the stated objects of the issue, and the company continues to manage its capital allocation in accordance with its strategic objectives.
Utilization of IPO Proceeds
As of the quarter ended March 31, 2026, the company has successfully completed the utilization of funds earmarked for high-priority areas. Previous objectives, including the repayment of indebtedness for both the parent company and its subsidiaries (Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited) and funding incremental working capital requirements, were fully realized in preceding quarters.
Strategic Reallocation and Growth
During the current reporting period, the company underwent a board-approved reallocation of funds. Approximately Rs 48.10 million in unutilized issue expenses were reallocated. Of this, Rs 23.10 million was directed toward inorganic growth initiatives through acquisitions, and Rs 25 million was assigned to general corporate purposes. These adjustments ensure that the capital remains aligned with the company’s long-term expansion goals and operational efficiency.
Financial Summary
The revised net proceeds for the issue stand at Rs 6,421.80 million. The company maintains a disciplined approach, ensuring that funds for general corporate purposes do not exceed 25% of the gross proceeds. All remaining unutilized funds, amounting to Rs 49.07 million, are currently held in the public offer account, awaiting deployment as per the company’s ongoing strategic requirements.
Source: BSE
